Navigation Links
Spherix Announces Second Quarter Financial Results
Date:8/12/2011

BETHESDA, Md., Aug. 12, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the three and six months ended June 30, 2011.

Recent and Upcoming Highlights

  • Pharmaceutical Development
  • Announced the recently licensed compound, SPX10624258 (SPX106), significantly reduced serum triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to LDLr -/- mice compared with controls [triglycerides: -36% (p=0.01), cholesterol -19% (p=0.01)]
  • Continued research contracts to investigate the role of D-tagatose in lowering triglycerides
  • Continued preclinical testing of SPX106 in combination with D-tagatose for treatment of high triglycerides and cholesterol
  • Began preclinical testing of SPX106 alone as a treatment for high triglycerides, atherosclerosis and the metabolic syndrome
  • Seeking a strategic partner for the continued development of D-tagatose as a treatment for Type 2 diabetes

  • Health Sciences Consulting
  • Recent and upcoming trade and professional shows:
  • April 9, 2011: Dr. Claire Kruger, Spherix CEO, spoke at the American Dietetic Association's Nutrition News Forecast 2011 in Chicago
  • May 16, 2011: Spherix Consulting's Principal Advisor, Dr. A. Wallace Hayes, presented at the American College of Toxicology's Toxicology for Industrial and Regulatory Scientists Program in Falls Church, Va.; his presentation, "Basic Principles of Toxicology," was co-authored by Dr. Kruger
  • July 26-27, 2011: Dr. Kruger, Dr. Hayes and Dr. Nancy Booth, Spherix's Senior Scienc
    '/>"/>

  • SOURCE Spherix Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Spherix Reports Second Quarter Earnings
    2. Growth Achieved in Spherixs Health Sciences Consulting Business
    3. Spherix D-tagatose to be Supplied by Inalco SpA
    4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
    5. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
    6. Spherix Elects New Independent Director, and Elects Chairman of the Board
    7. Spherix Reports First Quarter 2009 Earnings
    8. Spherix Announces Positive Phase 2 Study Results
    9. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
    10. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
    11. Spherix Reports Third Quarter 2009 Earnings
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
    (Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
    (Date:10/22/2014)... 22, 2014   Surefire Medical , Inc., the ... to maximize targeted delivery of embolization agents in minimally ... oncologist John R. Daniels , MD of the ... surgical oncologist Steven C. Katz , MD of ... Scientific Advisory Board (SAB).    "The role ...
    Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
    ... CEL-SCI Corporation,(NYSE: CVM ) announced today that ... with the National Institutes of Health Clinical Center,(NIHCC) ... M.D., to,investigate the molecular basis of changes to ... Dr. Marincola is the Chief of,the Infectious Disease ...
    ... Scientific Meeting -, ORLANDO, Fla., Oct. 7 ... Laboratories,Inc. (NYSE: FRX ) today announced the ... linaclotide,s safety and efficacy in 420 patients with,irritable ... data,indicates that once- daily oral dosing of linaclotide, ...
    Cached Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5
    (Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
    (Date:10/22/2014)... By Steven Reinberg ... -- Infants who quickly add weight and length may be ... study suggests. In adults, certain genes have been linked ... promote proportionate gains in fat and lean muscle, the researchers ... be heavier and taller. By ages 2 and 3, however, ...
    (Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
    (Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts to ... figures and forecasts on the global medical markets. , ... the Worldwide Medical Market Forecasts to 2019 ... the worldwide medical market to reveal key insights into ... for 2010-2019, covering each country market individually, allowing you ...
    (Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
    Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
    ... Heart Rate Monitor Technology Now Available in ... Commercial Fitness ... the leader in,heart rate monitoring and fitness assessment technology, announced ... heart rate monitors -- can now be seamlessly and cost-effectively,incorporated ...
    ... September 24, Nominations Now Being,Accepted, NEW YORK, ... Carl M. Loeb University Professor Emeritus at Harvard,University ... Laureates on the,committee responsible for awarding the most ... http://www.prix-galien-usa.com ) will be held on Wednesday, September ...
    ... April 14 Denise Kehoe has joined,medication therapy ... development. In her new role, she will manage ... of clients across the country., Kehoe brings ... and,operations experience to PharmMD. She recently served as ...
    ... reveals some promising substance use trends among Ontario adults, its ... significant public health flag. , First the more positive ... significantly declining from 28 percent in 1996 to 20 percent ... from 13 percent in 1996 to just 6 percent in ...
    ... National,Community Pharmacists Association (NCPA), representing approximately 23,000,independent ... about,pharmacy crime and offering tangible solutions during ... 18). At the forefront of the campaign ... Enforcement Executive Development,Association), and RxPatrol(R) from Purdue ...
    ... NEW YORK, April 14 When it comes ... often used,interchangeably, often confusing consumers. The Physicians Coalition ... "A label containing specific consumer safety information ... a drug or medical device has been,approved," explained ...
    Cached Medicine News:Health News:Polar Introduces Cost-Effective Solution to Reduce Heart Rate Data Cross-Talk 2Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 2Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 3Health News:PharmMD Announces Denise Kehoe as Vice President of Business Development 2Health News:Marijuana use on the rise among Ontario adults, CAMH reports 2Health News:NCPA Declares April 14 - 18 'Protect Your Pharmacy Week' 2Health News:Clarity on Cosmetic Injectable Labeling and Use 2Health News:Clarity on Cosmetic Injectable Labeling and Use 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: